Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare cancer susceptibility syndrome exclusively attributable to pathogenic variants in FH (HGNC:3700). This paper quantitatively weights the phenotypic context (PP4/PS4) of such very rare variants in FH.

Methods: We collated clinical diagnostic testing data on germline FH variants from 387 individuals with HLRCC and 1,780 individuals with renal cancer, and compared the frequency of 'very rare' variants in each phenotypic cohort against 562,295 population controls. We generated pan-gene very rare variant likelihood ratios (PG-VRV-LRs), and domain-specific likelihood ratios for missense variants (DS-VRMV-LR) using spatial clustering analysis, and log likelihood ratios (LLRs) as applicable within the updated ACMG/AMP Variant Classification Framework.

Results: For HLRCC, the PG-VRV-LR was estimated to be 2,669.4 (95% CI: 1,843.4-3,881.2, LLR 10.77) for truncating variants and 214.7 (185.0-246.9, LLR 7.33) for missense variants. For renal cancer, the PG-VRV-LR was 95.5 (48.9-183.0, LLR 6.23) for truncating variants and 5.8 (3.5-9.3, LLR 2.39) for missense variants. Clustering analysis in HLRCC cases revealed three 'hotspot' regions wherein the DS-VRMV-LR increased to 1226.9.

Conclusion: These data provide quantitative measures for very rare missense and truncating variants in FH, which reflect the differing phenotypic specificity of HLRCC and renal cancer, and may be applicable in clinical variant classification.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gim.2025.101565DOI Listing

Publication Analysis

Top Keywords

renal cancer
16
likelihood ratios
12
missense variants
12
truncating variants
12
variants
11
phenotypic specificity
8
germline variants
8
hereditary leiomyomatosis
8
leiomyomatosis renal
8
renal cell
8

Similar Publications

Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.

View Article and Find Full Text PDF

Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.

View Article and Find Full Text PDF

The NRF2/KEAP1 signaling pathway regulates the gene expression of numerous cytoprotective and detoxifying enzymes and is therefore essential for maintaining cellular redox homeostasis. Despite the increasing knowledge of NRF2 signaling complexity, dimethyl fumarate remains the sole NRF2-targeting therapy in clinical practice, used for multiple sclerosis. Ongoing research exploring the role of NRF2 in cancer, neurodegeneration, diabetes, and cardiovascular, renal, and liver diseases holds significant promise for future therapeutic innovation.

View Article and Find Full Text PDF

Background And Objective: Surgery of renal cell cancer (RCC) with a caval thrombus (CT) is associated with significant morbidity, particularly regarding thromboembolic complications. There are no data or recommendations regarding the potential benefit of preoperative anticoagulants. We aimed to assess the usefulness of preoperative anticoagulation regarding surgical outcomes and thromboembolic events in patients undergoing nephrectomy with inferior vena cava thrombectomy.

View Article and Find Full Text PDF